Patients’ clinical and procedural characteristics
| Total | RVOT stenting or prestenting (before TPVR) | Aortic coarctation stenting | Fontan-circulation fenestration closure | Miscellaneous | |
| Patients/stents, n (%) | N=170/N=183 | 106 (62.4)/114 (62.3) | 26 (15.3)/27 (14.7) | 21 (12.4)/22 (12) | 17 (10)/20 (10.9) |
| Male/adults, n (%) | 98 (57.6)/109 (64.1) | 59 (55.7)/83 (78.3) | 21 (80.8)/14 (53.8) | 10 (47.6)/2 (9.5) | 8 (47.1)/10 (58.8) |
| Age (years), median (IQR) | 23.6 (15.2–39.2) | 28.7 (18.7–44.4) | 18.5 (14.7–31.4) | 6.1 (5–8.5) | 21.8 (14–50.3) |
| Weight (kg), median (IQR) | 63.5 (47–75.7) | 67 (53.8–79) | 65 (58–77) | 20 (16.9–38) | 60 (34.5–66.5) |
| Minimal vessel diameter (mm), median (IQR) | 17.5 (12–22.8) | 20.7 (15.6–24.4) | 6 (3–12) | N/A | 7.9 (5.4–8.9) |
| Delivery sheath, n (%) | |||||
| Flexor Check-Flo (Cook Medical) | 65 (38.2) | 15 (14.2) | 24 (92.3) | 17 (81) | 9 (52.9) |
| GORE DrySeal Flex (W.L. Gore & Associates) | 105 (61.8) | 91 (85.8) | 2 (7.7) | 4 (19) | 8 (47.1) |
| Delivery sheath size (Fr), median (IQR) | 24 (12–26) | 26 (26–26) | 12 (12–14) | 11 (11–11) | 14 (10–20) |
| Dual DB, n (%) | 157 (92.4) | 106 (100) | 24 (92.3) | 11 (52.4) | 16 (94.1) |
| TED (=DB diameter) (mm), median (IQR) | 24 (18–28) | 26 (24–30) | 16 (15–19) | 18 (16–18) | 20 (12–24) |
| DB-to-stent length ratio, median (IQR) | 0.93 (0.88–1.05) | 0.93 (0.88–1.05) | 0.93 (0.81–1.06) | 0.93 (0.91–1.05) | 0.93 (0.75–1.16) |
| Second stenting, n (%) | 13 (7.6) | 8 (7.5) | 1 (3.8) | 1 (4.8) | 3 (17.6) |
| Optimus stent size, n (%), N=183 | |||||
| L (9-ZIG) | 32 (17.5) | 6 (5.2) | 11 (40.7) | 9 (40.9) | 6 (30) |
| XL (12-ZIG) | 61 (33.3) | 30 (26.3) | 9 (33.3) | 13 (59.1) | 9 (45) |
| XXL (15-ZIG) | 90 (49.2) | 78 (68.4) | 7 (25.9) | – | 5 (25) |
| PTFE-covered stent/prophylactic use, n (%) | 86 (50.6)/43 (25.3) | 35 (33)/27 (26.2) | 20 (76.9)/14 (53.8) | 21 (100)/– | 10 (58.8)/2 (11.8) |
| Stent length (mm), median (IQR) | 43 (38–48) | 43 (43–57) | 43 (33–44) | 43 (35–43) | 43 (30–100) |
| High-pressure balloon redilation, n (%) | 63 (37.1) | 25 (23.6) | 17 (65.4) | 9 (42.8) | 12 (70.6) |
| Vessel postimplantation final diameter, median (IQR) | 21.4 (16.3–26) | 24.4 (21.3–28) | 15.3 (13.7–17.6) | 16.8 (15.7–18) | 14.9 (10–22) |
| PASE (%), median (IQR) | 95.2 (89–99.7) | 93.4 (87.1–97.9) | 95.6 (91.6–99.8) | 98.2 (92.2–100) | 93.4 (84.5–100) |
| PVE (%), median (IQR) | 23.5 (11.2–48.4) | 18.6 (8.8–35.8) | 161.8 (25.8–326.8) | N/A | 87.5 (42.8–191.3) |
| Stent length shortening (%), median (IQR) | 10.9 (6.1–15.1) | 13.7 (10.5–18.5) | 7 1.(8–9.8) | 6.3 (2.3–7.8) | 3.5 (1.3–6.6) |
| Sheath-in/sheath-out time (min), median (IQR) | 75 (50–110) | 89 (60–120) | 40 (35–72) | 47 (36–71) | 90 (50–120) |
| Fluoroscopy time (min), median (IQR) | 16.5 (12.2–24.8) | 20 (14.1–28.2) | 6.9 (5.4–14.5) | 12.9 (8.3–16.5) | 24 (12.5–31.3) |
| Kar (mGy), median (IQR) | 250 (108–510) | 324 (198–631) | 168 (64–483) | 36 (26–69) | 162 (123–413) |
| Total dose area product (µGy·m²), median (IQR) | 2292 (516–6096) | 3659 (1382–6823) | 1176 (461–3444) | 340 (237–656) | 1449 (805–8125) |
PASE=ratio of measured postimplantation diameter to TED.
PVE=(measured postimplantation diameter−minimal vessel diameter) divided by minimal vessel diameter.
DB, delivery balloon; Kar, cumulative air kerma at the patient entrance reference point; N/A, not applicable; PASE, percentage of intended stent expansion; PTFE, polytetrafluoroethylene; PVE, percentage of vessel expansion; RVOT, right ventricular outflow tract; TED, target expansion diameter; TPVR, transcatheter pulmonary valve replacement.